Quick Facts:
Grantee Institution: Adenoid Cystic Carcinoma Research Foundation
Research Focus: Adenoid Cystic Carcinoma
Grant: Yearly Proceeds from BLG 5K
2018: $52,303
2019: $45,164
2020: $80,000
2021: $100,000
2022: $70,000
2023: $65,000
2024: $40,000
TOTAL: $452,467
Gabe and ACCRF co-founder Marnie at the Inaugural Brave Like Gabe 5K
History
When Gabe was diagnosed Adenoid Cystic Carcinoma, one of her first calls was to Marnie Kaufman. Marnie was diagnosed with Adenoid Cystic Carcinoma of the Parotid Gland when she was 38. She was frustrated at the lack of ongoing ACC research and in 2005, with her husband Jeff, they formed ACCRF. For the past 18 years, amazing progress has been made regarding research and awareness of ACC, yet there’s still so much to be done!
Marnie and her husband Jeff became invaluable resources for Gabe and Justin as very few people are diagnosed with ACC each year. As the Brave Like Gabe Foundation took shape, Marnie and Jeff were again there with generous advice and support. Often for rare diseases there are limited resources which can the diagnosis, treatment and uncertainty so much more difficult. The Brave Like Gabe Foundation is honored to support ACCRF in bringing more resources and hope to rare cancer patients.
“When we learned that the American Cancer Society and the National Cancer Institute had never done ANY research into ACC, we were shocked and terrified. Along with a dedicated core of family, friends and researchers we were able to jumpstart a global, cutting-edge research effort. Since then, the generosity of ACCRF supporters has permitted a network of brilliant and productive ACC researchers to flourish.”
Grant Information
Grants from the Brave Like Gabe Foundation support ACCRF's research efforts. Please visit their website to read more about their recent accomplishments.
Adenoid Cystic Carcinoma Quick Facts:
Adenoid cystic carcinoma (ACC) is a rare cancer of secretory glands, typically originating in the head and neck region.
Afflicting about 10,000 Americans, ACC is diagnosed in about 1,200 new cases each year in the United States.
ACC’s progression is typically gradual and relentless. Its high propensity to recur has led to 15-year survival rates of around 40%
ACC is an equal-opportunity disease that might strike anyone. It is not inherited and is not associated with smoking, drinking, infection or ethnicity. Women comprise nearly two-thirds of ACC cases
ACC often afflicts young and middle-aged patients. The median age at diagnosis for ACC patients is a decade younger than for all cancer patients.
Credit: accrf.org